DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

News

ELIXIR Innovation and SME Forum: Genomics and Associated Data in National Healthcare Initiatives 15 January 2019

This free ELIXIR Innovation and SME Forum with a focus on Genomics and Associated Data in Nationa... Read more

Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle 11 December 2018

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more

Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody 10 December 2018

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more

Naxitamab Receives Positive Opinion for Orphan Medicinal Product Designation Approval in the EU 29 October 2018

NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development 26 October 2018

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement... Read more

Nordic countries lead from the front with new bioeconomy action plan 01 October 2018

The Nordic countries have launched an ambitious plan to fast-track the development of a sustainable bioeconomy... Read more

Y-mAbs Therapeutics Announces Pricing of Initial Public Offering 21 September 2018

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more

Danish industrial biotech company BioPhero ApS completes a €3 million seed investment and appoints new chairman of the board 17 September 2018

Press Release: 17th September 2018 Today, BioPhero ApS has announced the closing of a seed investment... Read more

Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma 21 August 2018

The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF,... Read more

Copyright 2018 DANISH BIO – DANSK BIOTEK. All rights reserved.

created by: Mastafu Design